Rituximab not noninferior to ocrelizumab for relapsing-remitting multiple sclerosis
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology.
Jun 14, 2023
0
2